Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients

BACKGROUND: Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple myeloma (RRMM) in pivotal clinical trials. However, their effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaji‐Kanayama, Yuka, Kobayashi, Tsutomu, Muramatsu, Ayako, Uchiyama, Hitoji, Sasaki, Nana, Uoshima, Nobuhiko, Nakao, Mitsushige, Takahashi, Ryoichi, Shimura, Kazuho, Kaneko, Hiroto, Kiyota, Miki, Wada, Katsuya, Chinen, Yoshiaki, Hirakawa, Koichi, Fuchida, Shin‐ichi, Shimazaki, Chihiro, Matsumura‐Kimoto, Yayoi, Mizutani, Shinsuke, Tsukamoto, Taku, Shimura, Yuji, Horiike, Shigeo, Taniwaki, Masafumi, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842705/
https://www.ncbi.nlm.nih.gov/pubmed/34124862
http://dx.doi.org/10.1002/cnr2.1476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842705/
https://www.ncbi.nlm.nih.gov/pubmed/34124862
http://dx.doi.org/10.1002/cnr2.1476

Ejemplares similares